Austrian syndrome, ceftriaxone-induced agranulocytosis and COVID-19

6Citations
Citations of this article
64Readers
Mendeley users who have this article in their library.
Get full text

Abstract

We present a case of a 75-year-old woman with Austrian syndrome: pneumonia, meningitis and endocarditis all due to Streptococcus pneumoniae. Transoesophageal echocardiogram demonstrated a large mitral valve vegetation with severe mitral regurgitation. She was treated with intravenous ceftriaxone and listed for surgical repair of her mitral valve. Preoperatively, she developed an idiosyncratic drug-induced agranulocytosis secondary to ceftriaxone, which resolved on cessation of the medication. However, while awaiting neutrophil recovery, she developed an acute deterioration, becoming critically unwell. This deterioration was multifactorial, with acute decompensated heart failure alongside COVID-19. After multidisciplinary discussion, she was considered too unwell for surgery and palliated.

Cite

CITATION STYLE

APA

McCulloch, J. E., Miller, A., Borcea, M., & Reid, J. (2021). Austrian syndrome, ceftriaxone-induced agranulocytosis and COVID-19. BMJ Case Reports, 14(1). https://doi.org/10.1136/bcr-2020-239355

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free